Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.52 |
| ▸ | HTR1A | P08908 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723872 | 0.90 | ADRA1A (0.51) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL7610554 | 0.88 | HTR1A (0.61) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL7607460 | 0.88 | HTR1A (0.49) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL6931408 | 0.88 | HTR1A (0.49) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL6546338 | 0.86 | HTR1A (0.72) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL7606427 | 0.86 | HTR1A (0.51) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| Hydrochloric Acid SCHEMBL6548221 | 0.85 | HTR1A (0.71) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL7608222 | 0.85 | HTR1A (0.47) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| Hydrochloric Acid SCHEMBL7540928 | 0.84 | DRD2 (0.48) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B | |
| SCHEMBL6930467 | 0.81 | HTR1A (0.73) | ADRA1AHTR1ASMN1; SMN2DRD4ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | claimed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | ADRA1A 525/4885HTR1A 1328/4885SMN1; SMN2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.